NCT06343948View on ClinicalTrials.gov

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

383

Participants

Timeline

Start Date

April 24, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
HR+HER2- Breast Cancer
Interventions
DRUG

BL-B01D1

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

Eribulin

Administration by intravenous bolus for a cycle of 3 weeks.

DRUG

Vinorelbine

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

Gemcitabine

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

Capecitabine

Oral administration for a cycle of 3 weeks.

Trial Locations (1)

Unknown

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

NCT06343948 - A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer | Biotech Hunter | Biotech Hunter